Skip to main content
. 2026 Jun 23;17:1722204. doi: 10.3389/fimmu.2026.1722204

Figure 2.

Panel A is a horizontal bar chart with symbols indicating patient responses and treatments over time since start of DVd-lite therapy, stratified by disease subtypes AL, MIDD, PGNMID, and LCPT. Panel B is a line graph showing reduction in proteinuria (g/24h) over a 12-month period for ten patients. Panel C is a line graph presenting UACR (mg/g·Cr) values for the same patients over 12 months, indicating general decrease after baseline. Panel D is a grouped bar chart comparing albumin (g/L) at diagnosis and post-treatment for ten patients, showing increased albumin post-treatment.

(A) Swimmer’s plots for the ten MGRS patients treated with DVd-lite regimen. Events are denoted in the figure legend. (B) Proteinuria and (C) UACR response from baseline to 12 months in patients who received at least two cycles of the DVd-lite regimen. (D) Changes in serum albumin levels of patients before and after treatment. PD, disease progression; NR, no response; PR, partial response; VGPR, very good partial response; CR, complete response; kidNR, kidney NR; kidPR, kidney PR; kidCR, kidney CR; ASCT, autologous stem cell transplantation. Patient 2 and 5 were evaluated using M-protein levels due to baseline dFLC levels below 20 mg/L.